InvestmentMay 20, 2026, 02:40 PM
Jupiter Neurosciences to raise $2.0M in direct offering
AI Summary
Jupiter Neurosciences, Inc. announced it has entered into a securities purchase agreement for a registered direct offering. The company will sell 7,142,858 shares of common stock, expecting to raise approximately $2.0 million in gross proceeds. The offering is anticipated to close around May 21, 2026, and the funds will support its therapeutic pipeline targeting central nervous system disorders and neuroinflammation. D. Boral Capital LLC is serving as the exclusive placement agent.
Key Highlights
- Jupiter Neurosciences to raise approximately $2.0 million in a registered direct offering.
- The offering involves the sale of 7,142,858 shares of common stock.
- D. Boral Capital LLC is acting as the exclusive placement agent for the offering.
- Closing of the offering is expected on or about May 21, 2026.
- Shares are being offered pursuant to an effective shelf registration statement on Form S-3.
- Jupiter Neurosciences is a clinical-stage biopharmaceutical company focused on CNS disorders.
- Its lead program, JOTROL(TM), is in a Phase IIa clinical trial for Parkinson's disease.
Price Impact
More from JUNS